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Abstract
Background: Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous
bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD).
Methods: Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were
conducted globally: one in apolipoprotein E ε4 carriers and another in noncarriers. Patients received bapineuzumab
0.5 mg/kg (both trials) or 1.0 mg/kg (noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change
from baseline to week 78 on the 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale and the
Disability Assessment for Dementia.
Results: A total of 683 and 329 patients completed the current carrier and noncarrier trials, respectively, which
were terminated prematurely owing to lack of efficacy in the two other phase 3 trials of bapineuzumab in AD. The
current trials showed no significant difference between bapineuzumab and placebo for the coprimary endpoints
and no effect of bapineuzumab on amyloid load or cerebrospinal fluid phosphorylated tau. (Both measures were
stable over time in the placebo group.) Amyloid-related imaging abnormalities with edema or effusion were
confirmed as the most notable adverse event.
Conclusions: These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical
endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared
with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed.
Trial registration: Noncarriers (3000) ClinicalTrials.gov identifier NCT00667810; registered 24 Apr 2008.
Carriers (3001) ClinicalTrials.gov identifier NCT00676143; registered 2 May 2008.
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Background
Immunotherapy with monoclonal antibodies has been
under investigation as a therapeutic approach to
Alzheimer’s disease (AD) [1, 2]. Bapineuzumab is a
monoclonal antibody specific to the N-terminus of the
amyloid β (Aβ) protein designed to decrease plaque
formation and promote clearance of Aβ [2–4]. In phase
2 studies in patients with mild to moderate AD, bapi-
neuzumab reduced phosphorylated tau (p-tau) protein
in cerebrospinal fluid (CSF) and 11C-Pittsburgh com-
pound B (PiB) average uptake visualized by positron
emission tomography (PET) [5, 6]. The findings pro-
vided a rationale for conducting separate trials in apoli-
poprotein E (ApoE) ε4 allele carriers and noncarriers
and for limiting the bapineuzumab dose in carriers to
minimize risk of amyloid-related imaging abnormalities
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with edema or effusion (ARIA-E; previously termed
vasogenic edema) [7].
The bapineuzumab phase 3 development program
consisted of four nearly identical phase 3 trials con-
ducted in parallel to evaluate the efficacy and safety of
intravenous (IV) bapineuzumab over 18 months in pa-
tients with mild to moderate AD. The other two trials
reported elsewhere were conducted primarily in the
United States: Study 302 in ApoE ε4 allele carriers
(ClinicalTrials.gov identifier NCT00575055) and Study
301 in noncarriers (ClinicalTrials.gov identifier NCT00
574132) [3]. These studies showed no benefit of bapi-
neuzumab on the cognitive or functional endpoints
assessed.
Here we report results from the two global phase 3 tri-
als of IV bapineuzumab in ApoE ε4 carriers (Study 3001,
ClinicalTrials.gov identifier NCT00676143) and noncar-
riers (Study 3000, ClinicalTrials.gov identifier NCT00
667810). Both trials were terminated prematurely be-
cause of lack of clinical efficacy observed in the 301 and
302 studies [3].
Methods
Study design
Studies 3000 and 3001 were multicenter, randomized,
double-blind, placebo-controlled, 18-month clinical trials
in which investigators evaluated the efficacy and safety
of bapineuzumab 0.5 mg/kg versus placebo (ratio 3:2)
in ApoE ε4 carriers (Study 3001) and bapineuzumab
0.5 mg/kg, 1.0 mg/kg, or placebo (ratio 3:3:4) in ApoE
ε4 noncarriers (Study 3000). Originally, Study 3000 in-
cluded a bapineuzumab 2.0 mg/kg dose, which was
discontinued because of a high rate of clinically symp-
tomatic ARIA-E. Patients randomized to the 2.0 mg/kg
group were reassigned to receive 1.0 mg/kg for the re-
mainder of the study, and the randomization ratio was
adjusted accordingly. Allocation of patients to treat-
ment groups using stratified block randomization pro-
ceeded through the entering of subject information by
the study coordinator or delegate and the dispenser
(unblinded pharmacist) into an interactive voice/web
response system. The dispenser was then provided with
a subject randomization number and treatment assign-
ment, and a confirmatory facsimile was sent to the dispen-
ser. Randomization was stratified by Mini Mental State
Examination (MMSE) scores (16–21; 22–26); concomitant
cholinesterase inhibitor and/or memantine use; substudy
participation; and, in the carrier study, number of copies
of ApoE ε4 allele (one allele; two alleles). Patients received
a total of six IV infusions of bapineuzumab or placebo
every 13 weeks, with brain magnetic resonance imaging
(MRI) monitoring for ARIA-E conducted at 6 weeks after
each infusion. There were three biomarker substudies: a
brain amyloid PET substudy, a CSF substudy, and a
volumetric magnetic resonance imaging (vMRI) substudy.
No interim analyses were planned or performed.
Inclusion criteria
Patients were eligible for enrollment if they were aged
50–88 years with a diagnosis of probable AD and had an
MMSE score of 16–26, inclusive, and a screening MRI
scan consistent with AD. Inclusion and exclusion criteria
were similar to those used in the 301/302 studies [3] and
are listed in Additional file 2.
Outcome measures
Coprimary efficacy endpoints were change from baseline
to week 78 in 11-item Alzheimer’s Disease Assessment
Scale–Cognitive subscale (ADAS-Cog/11) score and
Disability Assessment for Dementia (DAD) total score.
Change from baseline to week 78 in Dependence Scale,
Clinical Dementia Rating–Sum of Boxes (CDR-SOB),
and Neuropsychological Test Battery (NTB) total Z-
scores were additional endpoints. Prespecified secondary
biomarker endpoints included change from baseline to
week 71 in PiB-PET global cortical average (GCA) stan-
dardized uptake value ratio (SUVr) of five cortical re-
gions of interest (frontal, lateral temporal, parietal,
anterior cingulate, posterior cingulate/precuneus), CSF
p-tau, and brain volume assessed by brain boundary shift
integral (BBSI) on vMRI. PiB-PET and vMRI were read
centrally. Human plasma Aβx–40 peptide levels were mea-
sured using a validated electrochemiluminescence im-
munoassay method on a Meso Scale Discovery (Rockville,
MD, USA) platform, which had a range of quantification
from 50 to 3200 pg/ml in 100 % matrix with a minimum
required sample dilution of 1:2 and maximum sample di-
lution of 1:64. This platform had an interassay precision of
9 % and an intraassay precision of 5 %. CSF 181phospho-
tau concentrations were measured using the INNOTEST
enzyme-linked immunosorbent assay (ELISA) (Innoge-
netics, Ghent, Belgium), which had an interassay precision
of 3–6 % and an intraassay precision of 2–5 %. Samples
were tested pairwise per patient to reduce between-assay
run variability (i.e., baseline and postbaseline samples in
the same assay run and on the same microtiter ELISA
plate). All biosamples were analyzed in a centralized loca-
tion at the Janssen Alzheimer Immunotherapy Research &
Development Bioanalytical Development laboratory in
South San Francisco, CA, USA. All prespecified endpoints
are listed in Additional file 3.
Statistical methods
For the ApoE ε4 carrier study, approximately 480 patients
were to be randomized to bapineuzumab 0.5 mg/kg and
320 to placebo. This number of patients gave 90 %
power to detect a 2.21-point advantage for the
bapineuzumab group over placebo on ADAS-Cog/11
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total score and a 5.39-point advantage on DAD total
score at week 78. For the ApoE ε4 noncarrier study,
approximately 295 patients were to be randomized to
each bapineuzumab dose group (0.5 and 1.0 mg/kg)
and 400 patients to placebo, giving 90 % power to detect a
2.65-point advantage on ADAS-Cog/11 total score for a
bapineuzumab dose over placebo and a 6.56-point advan-
tage on DAD total score at week 78. The standard devia-
tions for the ADAS-Cog/11 total score and the DAD total
score used in the power calculation were 9.3 and 23.0, re-
spectively (based on previous studies). Planned substudy
enrollment in the carrier substudies was 80 patients for the
PiB-PET substudy, 300 for the CSF substudy, and 680 for
the vMRI substudy. In the noncarrier study, planned enroll-
ment was 90 patients for the PiB-PET substudy, 190 for the
CSF substudy, and 550 for the vMRI substudy.
Study populations
Study populations included Safety: all randomized patients
who received at least one infusion or portion of an infusion
of study drug; Modified intention-to-treat (mITT): subjects
in the Safety population who had a baseline assessment and
at least one postbaseline assessment of ADAS-Cog/11 and
DAD total scores; All PiB-PET, CSF, and vMRI: subjects in
the Safety population who were enrolled in the specified
substudy and had a valid baseline assessment and at least
one postbaseline measurement; PiB-PET: patients in the
All PiB-PET population who had a baseline SUVr ≥1.35,
the threshold for amyloid positivity, and had at least one post-
baseline measurement. A restricted maximum likelihood-
based mixed model for repeated measures (MMRM) was
used to analyze the coprimary efficacy endpoints. Primary
analysis was based on treatment difference using least squares
means, with factor levels weighted according to overall base-
line sample proportions. CSF biomarkers were analyzed using
analysis of covariance, since week 71 was the only postbase-
line assessment.
Results
Patient disposition
In the ApoE ε4 carrier study, 1099 patients were ran-
domized and 1093 were treated (654 bapineuzumab
0.5 mg/kg, 439 placebo) (Fig. 1). A total of 1081 patients
were included in the mITT population (650 bapineuzu-
mab, 431 placebo). Three hundred ninety-eight treated
patients (60.9 %) in the bapineuzumab group and 285
(64.9 %) in the placebo group completed the study
(60.5 % and 64.6 % of randomized subjects, respectively)
(Fig. 1). The most common reason for discontinuation
was study termination by the sponsor (13.5 % bapineu-
zumab, 14.8 % placebo). Withdrawal due to adverse
events (AEs) was higher for the bapineuzumab group
(9.0 %) than for the placebo group (7.3 %) (Fig. 1).
In the ApoE ε4 noncarrier study, 890 patients were
randomized with 885 treated (267 bapineuzumab
0.5 mg/kg, 263 bapineuzumab 1.0 mg/kg, 11 bapineuzu-
mab 2.0 mg/kg, 344 placebo) (Fig. 1). The mITT popula-
tion included 847 patients (255 bapineuzumab 0.5 mg/
kg, 253 bapineuzumab 1.0 mg/kg, 11 bapineuzumab
2.0 mg/kg, 328 placebo). Patients in the 2.0 mg/kg group
were not included in the primary efficacy analysis or
safety analysis. Three hundred twenty-nine treated pa-
tients (37.2 %) completed the study (102 [38.2 %], 94
[35.7 %], 9 [81.8 %], and 124 [36.0 %] in the bapineuzu-
mab 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, and placebo
groups, respectively). A total of 556 treated patients
withdrew, with the most common reason being sponsor
decision to terminate the study (48.3 %, 44.9 %, and
45.1 % in the bapineuzumab 0.5 mg/kg, 1.0 mg/kg, and
placebo groups, respectively); withdrawal due to AEs
was comparable across treatment groups (4.9 %, 4.9 %,
and 5.5 %, respectively) (Fig. 1).
Exposure
In the carrier study safety population, the median dur-
ation of exposure was 1.49 years in both groups. All six
infusions were administered to 57.4 % of patients in the
bapineuzumab 0.5 mg/kg group and 69.8 % in the pla-
cebo group. In the noncarrier study safety population,
the median duration of exposure was 1 year in all
groups. All six infusions were administered to 41.6 %,
38.3 %, and 40.9 % in the bapineuzumab 0.5 mg/kg,
bapineuzumab 1.0 mg/kg, and placebo groups, respect-
ively, in the mITT population (Table 1). Among the 11
patients in the 2.0 mg/kg group, the median duration of
exposure was 1 year and all six infusions were received
by 54.5 % of patients in the mITT population.
Demographics and baseline characteristics
In both studies, mean age at study baseline was similar
across treatment groups, and the majority of patients
were white and female (Table 1). Approximately 17 %
were Asian, as both studies recruited patients from 36
centers in Japan. The mean duration of AD diagnosis
ranged between 2.6 and 3.0 years, and ≥80 % in each
group were being treated with cholinesterase inhibitors
and/or memantine. The distribution of randomization
stratification factors was similar across groups; among
carriers, the majority of patients (approximately 77 %)
had a single ApoE ε4 allele.
Clinical efficacy
In the ApoE ε4 carrier study, there was no statistically
significant difference between the bapineuzumab 0.5 mg/kg
and placebo groups for ADAS-Cog/11 (p = 0.979) or DAD
(p = 0.973) (Fig. 2). Similarly, in noncarriers, no statistically
significant difference was observed for ADAS-Cog/11 or
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DAD between the bapineuzumab 0.5 mg/kg and placebo
groups (p = 0.057 and p = 0.459, respectively) or between
the bapineuzumab 1.0 mg/kg and placebo groups (p =
0.848 and p = 0.623, respectively). An analysis of coprimary
endpoints among completers yielded similar findings; no
significant differences were observed for ADAS-Cog/11 or
DAD in either study. For a subgroup analysis by disease se-
verity and ApoE ε4 carrier status, see Additional file 4:
Table S1.
Additional efficacy endpoints
At week 78, there were no significant differences be-
tween bapineuzumab and placebo in the NTB total
Z-score, CDR-SOB score, or Dependence Scale total
score in either study, with one exception: in the noncar-
rier study, there was a significant difference in favor of
bapineuzumab between bapineuzumab 0.5 mg/kg and
placebo on NTB total Z-score (difference 0.10,
p = 0.047). All additional efficacy endpoint data are
shown in Table 2.
Biomarkers
PiB-PET
Change from baseline to week 71 for PiB-PET GCA
SUVr was not statistically significant versus placebo in
either study (Fig. 3a). Fifty-seven patients were enrolled
in the ApoE ε4 carrier substudy and 39 in the noncarrier
substudy. Twenty-three percent of patients did not
meet the threshold of SUVr for the GCA region of
interest ≥1.35 at baseline on PiB-PET in noncarriers (vs
2 % of carriers); all amyloid-negative patients were ex-
cluded from the PiB-PET population analysis. Baseline
values of PiB-PET GCA SUVr (mean [standard devi-
ation]) were similar between carriers: 2.2 (0.29) in the
Fig. 1 Disposition of patients with Alzheimer’s disease in the apolipoprotein E ε4 carrier and noncarrier studies. Recruitment and follow-up
occurred between 28 May 2008 and 3 December 2012 for the carrier study and between 25 June 2008 and 27 November 2012 for the noncarrier
study. ARIA-E, amyloid-related imaging abnormalities with edema or effusion; BAP, bapineuzumab; N/A, not applicable; PBO, placebo. aSubject
participation status is unknown for five subjects (one in PBO group, four in BAP group) owing to missing conclusion of patient participation in
study and/or conclusion of patient participation in treatment electronic case report form pages. Four of these subjects completed six infusions
and the week 78 visit. One subject completed four infusions and the week 45 visit
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placebo group and 2.2 (0.31) in the bapineuzumab
group, and noncarriers: 2.1 (0.21) in the placebo group
and 2.1 (0.24) in the pooled bapineuzumab group. A plot
of the baseline values for all patients screened for the PiB-
PET substudy (Fig. 4) shows the separation between non-
carriers who were classified as amyloid-negative and those
who were classified as amyloid-positive. A total of 14 non-
carriers and 27 carriers received the week 71 PET imaging
assessment. To estimate the effect of premature study
termination on statistical power, p values were calcu-
lated assuming that the data trend continued with full
enrollment in each study. The p value in the carrier
study was estimated to be 0.085 comparing bapineuzu-
mab with placebo, and the p value was estimated to be
0.438 in the noncarrier study comparing pooled bapi-
neuzumab with placebo.
CSF p-tau
The CSF carrier substudy enrolled 138 patients and the
noncarrier substudy enrolled 76. Nearly all had a base-
line and week 71 assessment. No significant differences
were observed in CSF p-tau, although in noncarriers the
difference showed a trend (p = 0.085) favoring the bapi-
neuzumab pooled group (Fig. 3b).
vMRI
The vMRI carrier substudy enrolled 540 patients and
the noncarrier substudy enrolled 401. No significant
treatment difference was observed in annualized rate
(milliliters per year) of whole-brain volume loss
assessed by BBSI in either study (Fig. 3c). In all groups,
the annual estimated decrease in whole-brain volume
was approximately 18 ml/year across all treatment
Table 1 Patient demographics and baseline characteristics (modified intention-to-treat population)
ApoE ε4 carrier study ApoE ε4 noncarrier study
Placebo (n = 431) BAP 0.5 (n = 650) Placebo (n = 328) BAP 0.5 (n = 255) BAP 1.0 (n = 253)
Mean age, years 70.2 70.9 69.7 71.1 70.7
Female, % 60.1 64.5 57.9 55.7 57.3
White, % 82.6 79.5 80.5 79.2 79.4
Asian, % 16.0 17.7 17.1 17.3 17.4
Black, % 0.7 0.8 0.6 0.8 2.0
Other, % 0.7 2.0 1.8 2.7 1.2
Mean duration of AD, years (SD) 2.9 (2.2) 3.0 (2.2) 2.8 (2.5) 2.6 (2.3) 2.9 (2.2)
ApoE ε4 allele status, n (%)
Heterozygous 334 (77.5) 500 (76.9) – – –
Homozygous 97 (22.5) 150 (23.1) – – –
Using anti-AD medication at baseline, n (%) 386 (89.6) 578 (88.9) 274 (83.5) 204 (80.0) 209 (82.6)
Mean MMSE score (SD) 21.0 (3.0) 20.9 (3.1) 20.8 (3.1) 20.8 (3.2) 20.8 (3.1)
Mean years of formal education (SD) 12.5 (3.6) 12.2 (3.7) 11.8 (3.9) 11.9 (3.9) 11.8 (3.9)
Substudy participation, n (%)
vMRI + PET or vMRI + PET + CSF 47 (10.9) 64 (9.8) 34 (10.4) 27 (10.6) 21 (8.3)
CSF or CSF + vMRI 104 (24.1) 160 (24.6) 67 (20.4) 44 (17.3) 53 (20.9)
vMRI only 161 (37.4) 241 (37.1) 112 (34.1) 92 (36.1) 88 (34.8)
No substudy 119 (27.6) 185 (28.5) 115 (35.1) 92 (36.1) 91 (36.0)
Mean ADAS-Cog/11 score (SD) 22.6 (8.9) 23.2 (8.9) 22.9 (10.2) 23.2 (10.0) 23.5 (9.3)
Mean DAD score (SD) 80.9 (18.7) 79.9 (18.3) 79.6 (17.9) 78.6 (20.0) 79.0 (18.4)
Infusions received, n (%)
1 13 (3.0) 34 (5.2) 40 (12.2) 22 (8.6) 29 (11.5)
2 17 (3.9) 42 (6.5) 44 (13.4) 37 (14.5) 46 (18.2)
3 29 (6.7) 57 (8.8) 36 (11.0) 31 (12.2) 25 (9.9)
4 28 (6.5) 46 (7.1) 33 (10.1) 24 (9.4) 26 (10.3)
5 43 (10.0) 98 (15.1) 40 (12.2) 35 (13.7) 30 (11.9)
6 301 (69.8) 373 (57.4) 134 (40.9)a 106 (41.6) 97 (38.3)
AD Alzheimer’s disease, ADAS-Cog/11 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale, ApoE apolipoprotein E, BAP bapineuzumab, CSF cerebrospinal
fluid, DAD Disability Assessment for Dementia, MMSE Mini Mental State Examination, PET positron emission tomography, vMRI volumetric magnetic resonance imaging
aOne patient in the placebo group received seven infusions
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groups at the first follow-up assessment (week 19) as
well as at subsequent assessments.
Pharmacodynamics
Significant increases in plasma Aβ levels with bapineu-
zumab from baseline to week 71 were observed in both
carrier (bapineuzumab-placebo difference 827.29 pg/ml,
p < 0.001) and noncarrier (pooled bapineuzumab-
placebo difference 941.86 pg/ml, p < 0.001) studies
(Fig. 3d).
Safety
Treatment-emergent adverse events (TEAEs) with >3 %
difference in incidence between groups were ARIA-E
and cerebral microhemorrhage (more with bapineuzu-
mab) and anxiety and headache (more with placebo).
For ApoE ε4 carriers, TEAEs considered treatment-
related were reported in 34.6 % of patients in the bapi-
neuzumab group and 22.1 % in the placebo group. In
the ApoE ε4 noncarrier study, the incidence of TEAEs
considered treatment-related was similar in the bapineu-
zumab 0.5 mg/kg and placebo groups (18.4 % and
Fig. 2 Primary efficacy outcome analysis: change from baseline to week 78. a ADAS-Cog/11: total score range is 0 (least impairment) to 70 (most
impairment). A positive change from baseline indicates worsening cognitive impairment. b DAD: total score range is 0 to 100, with higher scores
indicating better function. A negative change from baseline indicates worsening function. Data shown are least squares means with standard
error of the mean. ADAS-Cog/11, 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale; ApoE, apolipoprotein E; BAP, bapineuzumab;
DAD, Disability Assessment for Dementia; LS, least squares
Vandenberghe et al. Alzheimer's Research & Therapy  (2016) 8:18 Page 6 of 13
18.3 % of patients, respectively), but it was higher in the
bapineuzumab 1.0 mg/kg group (30.0 %). The incidences
of ARIA-E for ApoE ε4 carriers were 16.7 % for the
bapineuzumab 0.5 mg/kg group and 2.1 % for the pla-
cebo group. Discontinuation due to ARIA-E was higher
in the bapineuzumab group (2.9 % vs 0.5 %). All pre-
specified events of clinical importance other than
ARIA-E and hypersensitivity reactions were reported
in ≤1.2 % in both treatment groups (Table 3). Seizure,
deep vein thrombosis/pulmonary embolism, and intra-
cranial hemorrhage were numerically more frequent,
and hypersensitivity reaction was less frequent, in the
bapineuzumab group than in the placebo group. For
ApoE ε4 carriers, the incidences of intraparenchymal
hemorrhage were 0.46 % and 0.76 % in the placebo and
bapineuzumab groups, respectively (Table 3).
In noncarriers, incidences of ARIA-E were 4.9 % in
the bapineuzumab 0.5 mg/kg group, 11.8 % in the bapi-
neuzumab 1.0 mg/kg group, and 0.6 % in the placebo
group (Table 3). Discontinuation due to ARIA-E was
highest in the bapineuzumab 1.0 mg/kg group compared
with the bapineuzumab 0.5 mg/kg and placebo groups
(3.0 % vs 1.0 % and 0.6 %, respectively). All prespecified
AEs other than ARIA-E occurred in ≤2.0 % in all three
groups. Incidences of intracranial hemorrhage and seiz-
ure/convulsion were higher in the placebo group than in
either bapineuzumab group. There was one case of deep
vein thrombosis/pulmonary embolism in each of the
bapineuzumab groups and no cases in the placebo
group; no cases of intraparenchymal hemorrhage oc-
curred in the noncarrier study.
Discussion
The presently reported studies (3000/3001) are the last
of four phase 3 trials performed to evaluate bapineuzu-
mab immunotherapy. As in the first two U.S. trials
(Studies 301 and 302), no significant differences were
found in the coprimary cognitive or functional endpoints
in this more global demographic [3]. Early termination
of the 3000/3001 studies could have contributed to the
Table 2 Secondary and exploratory efficacy analyses: change from baseline to week 78
ApoE ε4 carrier study ApoE ε4 noncarrier study
PBO (n = 431) BAP 0.5 (n = 650) PBO (n = 328) BAP 0.5 (n = 255) BAP 1.0 (n = 253)
CDR-SOB total scorea
Number of subjects 310 427 144 115 110
Mean change (SD) 2.4 (2.8) 2.3 (2.9) 2.5 (2.8) 2.2 (2.8) 2.2 (2.6)
MMRM analysis
LS mean change (SE) 2.59 (0.16) 2.44 (0.13) 2.59 (0.20) 2.23 (0.23) 2.41 (0.23)
Difference vs PBO −0.15 −0.36 −0.18
p Value 0.448 0.238 0.564
DS total scoreb
Number of subjects 316 437 145 121 112
Mean change (SD) 1.2 (2.2) 1.2 (2.3) 1.4 (2.5) 1.3 (2.0) 1.1 (2.5)
MMRM analysis
LS mean change (SE) 1.33 (0.1) 1.22 (0.1) 1.45 (0.17) 1.29 (0.19) 1.16 (0.19)
Difference vs PBO −0.11 −0.16 −0.29
p Value 0.462 0.516 0.257
NTB total Z-scorec
Number of subjects 296 403 120 105 96
Mean change (SD) 0.0 (0.5) 0.0 (0.6) −0.1 (0.5) 0 (0.5) 0 (0.4)
MMRM analysis
LS mean change (SE) −0.11 (0.03) −0.10 (0.02) −0.09 (0.04) 0.02 (0.04) −0.12 (0.04)
Difference vs PBO 0.01 0.10 −0.03
p Value 0.889 0.047 0.541
ApoE apolipoprotein E, BAP bapineuzumab, CDR-SOB Clinical Dementia Rating–Sum of Boxes, DS Dependence Scale, LS least squares, MMRM mixed model for
repeated measures, NTB Neuropsychological Test Battery, PBO placebo
aCDR-SOB total score range is 0 (least impairment) to 18 (most impairment); a negative change from baseline indicates improvement
bDS total score range is 0–15, with higher scores indicating worse impairment; a negative change from baseline indicates improvement
cPositive change indicates improvement in NTB total Z-score
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Fig. 3 (See legend on next page.)
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inability to detect a treatment effect; however, enroll-
ment in the carrier (3001) study was complete (only the
PET substudy was still recruiting), MMRM analysis was
used, the treatment and placebo values were similar, and
the negative results in the mITT and completer popula-
tions were consistent with studies 301/302 collectively,
suggesting that the lack of clinical effect seen in these
two studies was not due to early termination. There was
no evidence of a clinical dose effect in the noncarrier
study between the 0.5 mg/kg and 1.0 mg/kg doses. The
small number of patients in the 2.0 mg/kg dose group
(11 patients, 9 completers) and the reassignment of
these patients to 1.0 mg/kg did not permit evaluation of
the effects of higher doses.
The need for earlier intervention with amyloid-
lowering therapy has been hypothesized as a potential
reason for lack of clinical efficacy observed in recent phase
3 studies of bapineuzumab and of solanezumab, another
anti-Aβ-targeted monoclonal antibody [2, 3, 8, 9]. Also, a
statistically significant benefit of bapineuzumab was re-
ported in Study 301 in a mild AD subgroup (MMSE >19)
of ApoE ε4 noncarriers on the functional but not the cog-
nitive measure [3]. On the basis of these findings, phase 3
studies in patients with mild AD and prodromal AD were
initiated with solanezumab and another anti-Aβ-targeted
monoclonal antibody, gantenerumab [10]. Twenty-three
percent of noncarriers and two percent of carriers who
had baseline PiB-PET scans met the clinical criteria for
AD dementia but did not meet the PiB-PET threshold for
amyloid positivity at baseline. These patients with “sus-
pected nonamyloid pathology” may have had some other
form of dementia that could not be differentiated from
AD on the basis of clinical inclusion criteria. Patients with
low levels of amyloid would not be expected to benefit
from an antiamyloid therapy. Inclusion of subthreshold
amyloid patients was also a factor in the 301/302 bapineu-
zumab PiB-PET substudies (36 % and 6.5 % of those with
baseline scans in the noncarrier and carrier studies, re-
spectively) [3]. The proportion of patients not meeting the
amyloid threshold was lower in the 3000/3001 studies
than in the 301/302 studies using the same threshold
value, suggesting some differences in enrollment between
the two sets of studies. The choice of amyloid threshold
was based on the consensus of experts consulted at the
time the studies were initiated, but the plot of baseline
values shows a clear separation between positive and
negative populations that would be robust to a range of
selected thresholds. The amyloid-negative patients were
included in the analyses of outcomes other than SUVr;
however, it is unlikely that exclusion of the ten patients
who were amyloid-negative would affect the overall study
outcome. Since brain amyloid positivity was not an inclu-
sion criterion, it is not possible to evaluate its impact on
the observed cognitive and functional outcomes. Collect-
ively, the findings from these studies indicate that amyloid
assessment at screening is essential and that meeting an
(See figure on previous page.)
Fig. 3 Analysis of biomarkers and plasma Aβ: change from baseline to week 71. Data shown are least squares means with standard error of the
mean. a PiB-PET analysis (b) CSF p-tau analysis (c) Volumetric analysis: An increase in BBSI on vMRI indicates a decrease in brain volume. d Plasma
Aβ analysis. Aβ, amyloid β; ApoE, apolipoprotein E; BAP, bapineuzumab; BBSI, brain boundary shift integral; CSF, cerebrospinal fluid; LS, least
squares; PiB-PET, 11C-Pittsburgh compound B positron emission tomography; p-tau, phosphorylated tau protein; SUVr, standardized uptake
value ratio; vMRI, volumetric magnetic resonance imaging. aExcludes nine patients who were PiB-PET-negative for Aβ at baseline
Fig. 4 Individual patient baseline PiB-PET SUVr values (all PiB-PET population). ApoE, apolipoprotein E; PiB-PET, 11C-Pittsburgh compound B positron
emission tomography; SUVr, standardized uptake value ratio
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agreed amyloid threshold should be an inclusion criterion
for future antiamyloid therapy trials.
The 3000/3001 bapineuzumab studies did not fully
replicate the PiB-PET or CSF biomarker findings from
Studies 301/302. In Studies 3000/3001, no significant
treatment differences were seen in amyloid burden on
PiB-PET or CSF p-tau (but trends were in the expected
directions) (Fig. 3b), which appeared to be related to sta-
bility of the placebo groups over time. This finding dif-
fers from the results of Study 302 in ApoE ε4 carriers, in
which SUVr on PiB-PET continued to increase in the
placebo group with no change in the bapineuzumab
group, suggesting prevention of Aβ accumulation. Sig-
nificant decreases in amyloid load on PiB-PET with
bapineuzumab were also reported from a phase 2 study
[6]. However, Study 301 in noncarriers showed no
change in SUVr in the placebo group and no significant
difference at week 71 between placebo and the bapineu-
zumab 0.5 mg/kg and 1.0 mg/kg groups [3]. Mean amyl-
oid load at baseline in amyloid-positive patients was
similar between carriers and noncarriers in all four stud-
ies and between the 301/302 and 3000/3001 studies. A
possible reason for lack of significance of the PiB-PET
results in Studies 3000/3001 is the small number of sub-
jects who completed each PiB-PET substudy, owing to
early study termination. Only 27 patients in the current
carrier study and 14 in the noncarrier study
(approximately half in the bapineuzumab and half in the
placebo group in each study) had an assessment at week
71, in contrast to 115 patients (75 bapineuzumab, 40
placebo) in the 302 carrier study and 39 patients (24
bapineuzumab, 15 placebo) in the 301 noncarrier study
[3]. However, the projected p values for the PET substu-
dies assuming full enrollment with the observed data
trends suggest that full enrollment would not have chan-
ged the study conclusions. The cerebellar gray matter
was used as reference region in the PET analyses, open-
ing up another possibility that the use of the pons as ref-
erence region might have reduced the noise and thereby
improved sensitivity to detect changes [11].
In Studies 3000/3001, there was no effect of treatment
on CSF p-tau, although there was a trend for significant
reduction in the pooled bapineuzumab group in noncar-
riers. This finding differs from the results of the 301/302
studies. In ApoE ε4 noncarriers in the latter studies,
there was no effect on CSF p-tau concentrations in the
pooled bapineuzumab groups (the prespecified analysis),
but exploratory analyses showed a significant reduction
in CSF p-tau with bapineuzumab 1.0 mg/kg [3]. As was
the case for the PiB-PET analysis of SUVr, the results for
CSF p-tau in the current studies were likely affected by
the small number of patients who completed the assess-
ments. Compared with the 301/302 studies, the number
of patients in the bapineuzumab groups was less by almost
Table 3 Prespecified events of clinical importance—incidence proportion (95% CI)
Event, n, % (95% CI) ApoE ε4 carrier study ApoE ε4 noncarrier study
Placebo BAP 0.5 Placebo BAP 0.5 BAP 1.0
(n = 439) (n = 654) (n = 344) (n = 267) (n = 263)
ARIA-E 9 109 2 13 31
2.05 16.67 0.58 4.87 11.79
(0.94, 3.86) (13.89, 19.75) (0.07, 2.08) (2.62, 8.18) (8.15, 16.3)
Intracranial hemorrhage 5 6 7 2 1
1.14 0.92 2.03 0.75 0.38
(0.37, 2.64) (0.34, 1.99) (0.82, 4.15) (0.09, 2.68) (0.01, 2.10)
Seizures/convulsions 1 7 3 1 0
0.23 1.07 0.87 0.37 0.00
(0.01, 1.26) (0.43, 2.19) (0.18, 2.53) (0.01, 2.07) (0.00, 1.39)
DVT/PE 2 8 0 1 1
0.46 1.22 0.00 0.37 0.38
(0.06, 1.64) (0.53, 2.40) (0.00, 1.07) (0.01, 2.07) (0.01, 2.10)
Hypersensitivity reactions 19 18 6 5 4
4.33 2.75 1.74 1.87 1.52
(2.63, 6.68) (1.64, 4.32) (0.64, 3.76) (0.61, 4.32) (0.42, 3.85)
Intraparenchymal hemorrhage 2 5 0 0 0
0.46 0.76 0.00 0.00 0.00
(0.06, 1.64) (0.25, 1.78) (0.00, 1.07) (0.00, 1.37) (0.00, 1.39)
ApoE apolipoprotein E, ARIA-E amyloid-related imaging abnormalities, edema/effusion, BAP bapineuzumab, DVT/PE deep vein thrombosis/pulmonary embolism
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half. vMRI assessments showed no significant effect of
bapineuzumab treatment in any of the four studies, and
rates of whole-brain volume loss were similar [3].
Plasma Aβx–40 levels increased significantly in the
bapineuzumab groups but not in the placebo group in
the 3000/3001 studies, a result expected from anti-Aβ
antibody infusion observed in other studies and an indi-
cator of peripheral target engagement [2, 9].
Infusions of bapineuzumab 0.5 and 1.0 mg/kg every
13 weeks were generally well-tolerated, and the safety pro-
file was consistent with that reported in previous studies.
No new or unexpected safety findings were observed [3, 7].
ARIA-E were confirmed as dose-dependent TEAEs associ-
ated with bapineuzumab; these events increased with dose
and ApoE ε4 allele number and led to discontinuation of
the 2.0 mg/kg dose in all noncarrier studies [3]. Rates of
ARIA-E were three to four times higher in the placebo
group of ApoE ε4 carriers than among noncarriers in the
current studies, which differs from what was reported in
the previous studies. This difference may have been due to
increased detection because of the central image-reading of
every MRI scan, suggesting a need for more intensive radi-
ologist training to detect ARIA-E, particularly in clinical tri-
als. Further research is needed to identify risk factors for
ARIA-E and their long-term clinical course [12]. There is
growing evidence that ARIA is related to amyloid clearance
from the brain [12], which could eventually be tested by
comparing PET and MRI images from the four completed
bapineuzumab studies.
Study limitations
Early termination is the major limitation of both studies,
as both were discontinued earlier than expected and be-
fore enrollment was complete in the noncarrier study.
Premature termination led to smaller-than-expected
sample sizes, particularly in the PiB-PET and CSF p-tau
substudies. In addition, assuming that the PET substudy
population is representative of the entire study popula-
tion, a relatively high proportion of ApoE ε4 noncarriers
did not meet a preestablished amyloid threshold and
therefore lacked the drug target.
Conclusions
Despite early termination, these studies in a more global
population demographic confirm the overall negative
clinical findings of the first phase 3 trials of bapineuzumab
in mild to moderate AD. Some biomarker results of the
301/302 studies were not confirmed in the present studies,
although small sample sizes limit their interpretation. In
the future, a pooled analysis of the data from the four stud-
ies may provide more clarity on the effects of bapineuzu-
mab on biomarkers of AD. In the PiB-PET substudy, the
percentage of ApoE ε4 noncarriers with amyloid below the
GCA threshold SUVr of 1.35 is lower in this study than in
Study 301 (23 % vs 36 %). Assuming that the percentage
is similar in the entire study population, it is still high
and highlights the potential importance of meeting a
preestablished amyloid threshold as an inclusion criter-
ion when conducting future studies of this type. Prelim-
inary studies to determine adequate blood-brain barrier
penetration of therapeutic antibodies at planned study
doses would also help answer questions about central
target engagement. Large studies in patients with pro-
dromal AD who have sufficient brain amyloid to con-
firm the diagnosis, with extended follow-up to ensure
significant change from baseline in the placebo group,
will likely be needed to ultimately determine the viabil-
ity of an immunotherapeutic approach to AD
treatment.
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